Abstract

This work describes protocols for preparing specific forms of human platelet lysates from pooled platelet concentrates (PCs) and the isolation of platelet-derived extracellular vesicles (p-EVs). Clinical-grade PCs can be sourced from blood establishments immediately following expiration for transfusion use. Here, we describe methods to process PCs into specific lysates from which p-EVs can be isolated. Each lysate type is prepared using platelet activation and processing methods which produce distinct products that may be useful in different applications. For example, serum-converted platelet lysate (SCPL)-EVs were recently shown to have powerful therapeutic properties following myocardial infarction in mice. EVs can be isolated from all products using size exclusion chromatography, producing pure and consistent p-EVs from multiple batches. Together, these methods allow isolation of p-EVs with excellent potential for clinical and preclinical applications. • Platelet concentrates (PCs) obtained from local blood establishments are reliable and sustainable sources to generate biomaterials. • We outline five distinct methods of platelet lysate generation and one method for extracellular vesicle isolation. • Each platelet lysate form has different biological properties which may be suitable for certain applications.

Original languageEnglish
Article number102822
JournalMethodsX
Volume13
DOIs
Publication statusPublished - Dec 2024

Keywords

  • Biomaterial
  • Bioprocessing
  • Blood-based therapeutic
  • Exosome
  • Size exclusion chromatography

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Medical Laboratory Technology

Fingerprint

Dive into the research topics of 'Bioprocessing of human platelet concentrates to generate lysates and extracellular vesicles for therapeutic applications'. Together they form a unique fingerprint.

Cite this